Article
Oncology
Jiajia Gao, Lusong Tian, Yulin Sun, Wei Li, Lina Zhao, Yan Sun, Zongpan Jing, Lanping Zhou, Fang Liu, Xiaohang Zhao
Summary: PUR alpha promotes cell growth, migration, and invasion in ESCC, likely through inducing EMT to contribute to the progression of ESCC. High expression of PUR alpha is associated with lymph node metastasis, advanced AJCC stage, and worse survival outcomes in ESCC patients.
Article
Biochemistry & Molecular Biology
Zheng Wu, Yan Li, Yunfeng Niu, Juntao Lu, Zhaoyang Yan, Tongxin Xu, Yanli Guo, Zhiming Dong, Wei Guo
Summary: FOXD3 is significantly downregulated in esophageal squamous cell carcinoma (ESCC) and correlates with clinical features such as patient survival and lymph node metastasis. FOXD3 inhibits migration and invasion of ESCC cells and participates in TGF-β1 induced epithelial-mesenchymal transition. Furthermore, a positive correlation between FOXD3 and SMAD family member 7 (SMAD7) was found in ESCC.
MOLECULAR CARCINOGENESIS
(2021)
Article
Oncology
Boli Yang, Qiuyu Chen, Changshan Wan, Siyuan Sun, Lanping Zhu, Zhizhong Zhao, Weilong Zhong, Bangmang Wang
Summary: Transgelin is found to be expressed at low levels in ESCC, and its expression is positively correlated with the prognosis of ESCC patients. It inhibits the malignant progression of ESCC by suppressing the occurrence of EMT, as its overexpression significantly reduces cell invasion and proliferation abilities, while its knockdown promotes cell proliferation, migration, and invasion.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Adria Bernat-Peguera, Juan Navarro-Ventura, Laura Lorenzo-Sanz, Victoria da Silva-Diz, Mattia Bosio, Luis Palomero, Rosa M. Penin, Diana Perez Sidelnikova, Josep Oriol Bermejo, Miren Taberna, Noelia Vilarino, Josep M. Piulats, Ricard Mesia, Joan Maria Vinals, Eva Gonzalez-Suarez, Salvador Capella-Gutierrez, Alberto Villanueva, Francesc Vinals, Purificacion Munoz
Summary: EGFR-targeted therapy may be effective for treating cSCCs conserving epithelial traits, but resistance may occur in tumors with the E545K PIK3CA-activating mutation. Some initially responding tumors develop resistance after long-term treatment, induced by bypassing from EGFR signaling to FGFR signaling. Pharmacologic inhibition of FGFR signaling can overcome resistance to EGFR inhibitors.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Sima Ardalan Khales, Sina Mozaffari-Jovin, Dirk Geerts, Mohammad Reza Abbaszadegan
Summary: This study reveals the crucial role of TWIST1 in the establishment of a cancer stem cell-like phenotype, EMT progression, and inhibition of apoptosis in esophageal squamous cell carcinoma (ESCC). These findings provide evidence for TWIST1 as a therapeutic target for suppressing CSC generation and ESCC malignancy.
Article
Multidisciplinary Sciences
Shaoqiu Zheng, Jing Luo, Shoucheng Xie, Shanming Lu, Qinghua Liu, Huanqin Xiao, Wenjuan Luo, Yanfang Huang, Kun Liu
Summary: Recent evidence suggests that cancer stem cells (CSCs) are the origin of cancers. This study investigated the relationship between tumor buds, which are hypothesized to represent epithelial-mesenchymal transition (EMT)-like CSCs, and EMT and CSC markers in cervical squamous cell carcinoma (CxSCC). The findings indicate that tumor buds in CxSCC may represent EMT-like CSCs in vivo.
Article
Oncology
Yamei Chen, Shihao Zhu, Tianyuan Liu, Shaosen Zhang, Junting Lu, Wenyi Fan, Lin Lin, Tao Xiang, Jie Yang, Xuan Zhao, Yiyi Xi, Yuling Ma, Guoyu Cheng, Dongxin Lin, Chen Wu
Summary: In this study, a comprehensive analysis of 79 multistage esophageal lesions from 29 ESCC patients was conducted using single-cell RNA sequencing and spatial transcriptomics. The results showed a gradual loss of ANXA1 expression in epithelial cells during lesion progression, which was attributed to the suppression of its transcription factor KLF4. It was also found that ANXA1 is a ligand for fibroblasts and loss of ANXA1 leads to uncontrolled transformation of normal fibroblasts into cancer-associated fibroblasts (CAFs), facilitated by TGF-b secreted by malignant epithelial cells. This highlights the importance of ANXA1/FPR2 signaling in the crosstalk between epithelial cells and fibroblasts in promoting ESCC.
Article
Oncology
Yen-Hao Chen, Hung- Lu, Chien-Ming Lo, Shau-Hsuan Li
Summary: CD73 is a key molecule in tumor immune suppression and is associated with worse outcomes in various cancers. Its overexpression promotes the malignant properties of cancers and affects the efficacy of immunotherapy.
Article
Oncology
Yifei Liu, Xiaohui Zhu, Wenwen Zhang, Tingting Bian, Zheng Wu, Jianguo Zhang, Hongmei Qiu, Yingzi Hu, Jia Feng, Jiahai Shi
Summary: Growing evidence suggests that RASSF10 is a novel tumor-suppressor gene involved in the inhibition of tumor progression and metastasis in esophageal squamous cell carcinoma (ESCC). This study investigated the role of RASSF10 in ESCC and found that it is downregulated in ESCC tissues and closely correlated with tumor progression and patient prognosis. Functional studies demonstrated that RASSF10 overexpression inhibits cell growth, colony formation, migration, and invasion of ESCC cells and activates the Wnt/β-catenin pathway. These findings suggest that RASSF10 may serve as a prognostic factor and a therapeutic target in ESCC.
Article
Oncology
Tao Liu, Xiujuan Han, Shutao Zheng, Qing Liu, Aerziguli Tuerxun, Qiqi Zhang, Lifei Yang, Xiaomei Lu
Summary: CALM1 and EGFR are significantly overexpressed in ESCC, associated with clinical stage and poor prognosis. Knock-out of CALM1 combined with EGFR inhibitor can inhibit ESCC cell proliferation, induce cell cycle arrest, increase apoptosis, and suppress invasion and migration in vitro.
CANCER CELL INTERNATIONAL
(2021)
Review
Oncology
Kewei Song, Chenhui Ma, Baohong Gu, Bofang Wang, Huanhuan Ma, Xiaobo Deng, Hao Chen
Summary: Esophageal cancer is a prevalent malignancy worldwide and is a leading cause of cancer-related death. Esophageal squamous cell carcinoma is the most common subtype of esophageal cancer, and cisplatin is commonly used for its treatment. However, drug resistance has become a significant challenge in clinical treatment.
Article
Oncology
Leonardo Franz, Lorenzo Nicole, Anna Chiara Frigo, Giancarlo Ottaviano, Piergiorgio Gaudioso, Tommaso Saccardo, Francesca Visconti, Rocco Cappellesso, Stella Blandamura, Ambrogio Fassina, Gino Marioni
Summary: The mechanism of epithelial-mesenchymal transition (EMT) plays a crucial role in cancer development, tumor progression, and therapy resistance. In laryngeal carcinoma, the predictive value of pN+ status and Slug expression on disease-free survival was identified, supporting the hypothesis of a mutual concurrence of EMT and angiogenesis in driving aggressive phenotype in LSCC. Further studies are needed to characterize the predictive performance of prognostic models based on EMT and angiogenesis.
Article
Food Science & Technology
Ji Feng, Yin Xu, Zhouling Wei, Yiju Xia, Haoxiang Zhang, Caifei Shen, Pu Wang, Wu Yan, Dianchun Fang, Yu Fang
Summary: This study aimed to investigate the effects of capsaicin on invasion and metastasis of esophageal squamous cell carcinoma (ESCC) and the underlying mechanisms. It was found that Cldn3 expression in ESCC was associated with better prognosis. Capsaicin inhibited migration, invasion, and metastasis of ESCC by overexpressing Cldn3 and inhibiting EMT.
JOURNAL OF FUNCTIONAL FOODS
(2022)
Article
Oncology
Chunhua Xu, Shan Lin, Yanxin Lu, Longyi Mao, Shi Li, Zesong Li
Summary: C12orf59 is overexpressed in esophageal squamous cell carcinoma (ESCC), promoting cell proliferation, migration, and invasion. It exerts its oncogenic function by inducing epithelial-mesenchymal transition (EMT) through the activation of Yes-associated protein (YAP).
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Zihang Ling, Bin Cheng, Xiaoan Tao
Summary: Oral squamous cell carcinoma (OSCC) is the most common malignancy in global oral cancer, with a low survival rate due to tumor metastasis and recurrence. Epithelial-to-mesenchymal transition (EMT) plays a key role in tumor metastasis and has attracted significant attention. Further research on the role of EMT in OSCC may provide novel insights for developing strategies to combat this type of cancer.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Editorial Material
Gastroenterology & Hepatology
Shuji Yamamoto, Kazuyoshi Matsumura, Hiroshi Seno
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2019)
Article
Gastroenterology & Hepatology
Kozo Ikuta, Akihisa Fukuda, Satoshi Ogawa, Kenji Masuo, Norihiro Goto, Yukiko Hiramatsu, Motoyuki Tsuda, Yoshito Kimura, Yoshihide Matsumoto, Yuto Kimura, Takahisa Maruno, Keitaro Kanda, Kiyoto Nishi, Kyoichi Takaori, Shinji Uemoto, Shigeo Takaishi, Tsutomu Chiba, Eiichiro Nishi, Hiroshi Seno
Article
Gastroenterology & Hepatology
Ayaka Mizumoto, Shinya Ohashi, Mayumi Kamada, Tomoki Saito, Yukie Nakai, Kiichiro Baba, Kenshiro Hirohashi, Yosuke Mitani, Osamu Kikuchi, Junichi Matsubara, Atsushi Yamada, Tsukasa Takahashi, Hyunjin Lee, Yasushi Okuno, Masashi Kanai, Manabu Muto
JOURNAL OF GASTROENTEROLOGY
(2019)
Article
Oncology
Kenshiro Hirohashi, Shinya Ohashi, Yusuke Amanuma, Yukie Nakai, Tomomi Ida, Kiichiro Baba, Yosuke Mitani, Ayaka Mizumoto, Yoshihiro Yamamoto, Osamu Kikuchi, Junichi Matsubara, Atsushi Yamada, Shin'ichi Miyamoto, Hiroshi Seno, Tomonari Matsuda, Manabu Muto
Article
Genetics & Heredity
Nilay S. Sethi, Osamu Kikuchi, Gina N. Duronio, Matthew D. Stachler, James M. McFarland, Ruben Ferrer-Luna, Yanxi Zhang, Chunyang Bao, Roderick Bronson, Deepa Patil, Francisco Sanchez-Vega, Jie-Bin Liu, Ewa Sicinska, Jean-Bernard Lazaro, Keith L. Ligon, Rameen Beroukhim, Adam J. Bass
Article
Oncology
Shinya Ohashi, Osamu Kikuchi, Yukie Nakai, Tomomi Ida, Tomoki Saito, Yuki Kondo, Yoshihiro Yamamoto, Yosuke Mitani, Trang H. Nguyen Vu, Keita Fukuyama, Hiroshi Tsukihara, Norihiko Suzuki, Manabu Muto
MOLECULAR CANCER THERAPEUTICS
(2020)
Article
Oncology
Osamu Maehara, Goki Suda, Mitsuteru Natsuizaka, Taku Shigesawa, Gouki Kanbe, Megumi Kimura, Masaya Sugiyama, Masashi Mizokami, Masato Nakai, Takuya Sho, Kenichi Morikawa, Koji Ogawa, Shinya Ohashi, Shingo Kagawa, Hideaki Kinugasa, Seiji Naganuma, Naoto Okubo, Shunsuke Ohnishi, Hiroshi Takeda, Naoya Sakamoto
Summary: Fibroblast growth factors (FGFs) and their receptors (FGFRs) play an important role in maintaining cancer stem-like cells in esophageal squamous cell carcinoma (ESCC). This study reveals that FGFR2, particularly the IIIb isoform, is highly expressed in non-CSCs, inducing keratinocyte differentiation and decreasing CSC populations. Analysis using The Cancer Genome Atlas (TCGA) dataset shows a significant correlation between FGFR2 expression and cancer cell differentiation in ESCC clinical samples, suggesting FGFR2-AKT signaling as a potential therapeutic target for ESCC.
CANCER BIOLOGY & THERAPY
(2021)
Article
Oncology
Takuya Sho, Goki Suda, Yoshiya Yamamoto, Ken Furuya, Masaru Baba, Koji Ogawa, Akinori Kubo, Yoshimasa Tokuchi, Qingjie Fu, Zijian Yang, Megumi Kimura, Takashi Kitagataya, Osamu Maehara, Shunsuke Ohnishi, Akihisa Nakamura, Ren Yamada, Masatsugu Ohara, Naoki Kawagishi, Mitsuteru Natsuizaka, Masato Nakai, Kazuharu Suzuki, Takaaki Izumi, Takashi Meguro, Katsumi Terashita, Tomofumi Takagi, Jun Ito, Tomoe Kobayashi, Takuto Miyagishima, Naoya Sakamoto
Summary: The combination of atezolizumab and bevacizumab is equally effective for patients with unresectable hepatocellular carcinoma (HCC) who meet or do not meet the eligibility criteria of the IMbrave150 trial. However, careful monitoring of liver functional reserve is necessary for patients not meeting the trial criteria.
Article
Pharmacology & Pharmacy
Tomoyuki Abe, Yoshihito Horisawa, Osamu Kikuchi, Hitomi Ozawa-Umeta, Atsuhiro Kishimoto, Yasuhiro Katsuura, Atsushi Imaizumi, Tadashi Hashimoto, Kotaro Shirakawa, Akifumi Takaori-Kondo, Kosuke Yusa, Tadashi Asakura, Hideaki Kakeya, Masashi Kanai
Summary: Curcumin 13-D-glucuronide sodium salt (TBP1901), a prodrug form of aglycone curcumin, has been found to have significant antitumor effects in vivo. The conversion of TBP1901 into aglycone curcumin is dependent on the enzyme glucuronidase (GUSB). Additionally, aglycone curcumin inhibits NF-kappa B signaling pathways and induces the production of reactive oxygen species (ROS) to exert its antitumor effects.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2022)
Article
Virology
Naoki Kawagishi, Goki Suda, Yoshiya Yamamoto, Masaru Baba, Ken Furuya, Osamu Maehara, Shunsuke Ohnishi, Sonoe Yoshida, Qingjie Fu, Zijian Yang, Shunichi Hosoda, Yoshimasa Tokuchi, Takashi Kitagataya, Masatsugu Ohara, Kazuharu Suzuki, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Koji Ogawa, Naoya Sakamoto
Summary: This study evaluated the predictive value of serum Ang2 levels for the occurrence and recurrence of HCC after treatment with direct-acting antiviral (DAA) medication in HCV-infected patients. The results showed that age ≥75 years and baseline Ang2 levels ≥464 pg/mL were significantly associated with the occurrence of HCC after DAA therapy. The combination of age and baseline Ang2 levels could distinguish between high and low-risk groups for HCC after DAA therapy. Furthermore, baseline Ang2 levels ≥402 pg/mL were significantly associated with HCC recurrence in patients who achieved sustained virological response with DAAs. In conclusion, serum Ang2 levels can predict the occurrence and recurrence of HCC after successful eradication of HCV by DAAs.
Article
Oncology
Zijian Yang, Goki Suda, Osamu Maehara, Masatsugu Ohara, Tomoka Yoda, Takashi Sasaki, Risako Kohya, Sonoe Yoshida, Shunichi Hosoda, Yoshimasa Tokuchi, Takashi Kitagataya, Kazuharu Suzuki, Naoki Kawagishi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Koji Ogawa, Shunsuke Ohnishi, Naoya Sakamoto
Summary: The mechanisms of resistance to atezolizumab/bevacizumab for unresectable HCC and the subsequent response to these therapies are not well understood. This study evaluated the changes in serum growth factors in 46 patients receiving atezolizumab/bevacizumab for unresectable HCC. Patients with disease control showed an increase in FGF-19 and a decrease in ANG2 at the best overall response point. Patients who experienced disease progression after disease control showed an increase in VEGF-D and ANG2 at the progression point compared to the best overall response point. Increased serum levels of VEGF-D and ANG-2 may contribute to resistance to atezolizumab/bevacizumab in unresectable HCC.
Article
Medicine, Research & Experimental
Tianxia Li, Osamu Kikuchi, Jin Zhou, Yichen Wang, Babita Pokharel, Klavdija Bastl, Prafulla Gokhale, Aine Knott, Yanxi Zhang, John G. Doench, Zandra V. Ho, Daniel V. T. Catenacci, Adam J. Bass
Summary: Gastroesophageal adenocarcinomas (GEAs) frequently exhibit amplification of KRAS gene, resulting in overexpression of WT KRAS protein. This study investigates potential targets to enhance the efficacy of SHP2 inhibition in KRAS-amplified GEA, including those within the MAPK pathway and upstream RTKs. In vitro and in vivo experiments demonstrate that pan-ERBB kinase inhibition has potent cytotoxicity. Additionally, the combination of CDK4/6 inhibition with SHP2 inhibition shows greater efficacy in KRAS-amplified GEA compared to KRAS-mutant tumors. These findings suggest potential therapeutic combinations for clinical study in KRAS-amplified GEAs.
Correction
Cell Biology
Norihide Jo, Yu Hidaka, Osamu Kikuchi, Masaru Fukahori, Takeshi Sawada, Masahiko Aoki, Masaki Yamamoto, Miki Nagao, Satoshi Morita, Takako E. E. Nakajima, Manabu Muto, Yoko Hamazaki
Article
Cell Biology
Norihide Jo, Yu Hidaka, Osamu Kikuchi, Masaru Fukahori, Takeshi Sawada, Masahiko Aoki, Masaki Yamamoto, Miki Nagao, Satoshi Morita, Takako E. Nakajima, Manabu Muto, Yoko Hamazaki
Summary: Impaired CD4(+) T cell responses in older adults result in weaker humoral and cellular immunity and reduced systemic reactogenicity after mRNA COVID-19 vaccination. Older adults show fewer spike-specific CD4(+) T cells, including CXCR3(+) circulating follicular helper T cells and T(H)1 helper T cells, after the first dose, correlated with lower IgG levels and fewer adverse effects after the second dose compared to younger adults. Inefficient CD4(+) T cell response after the first dose may lead to decreased production of helper T cytokines, resulting in lower immune response and reduced reactogenicity.
Article
Gastroenterology & Hepatology
Takashi Kijima, Hiroshi Nakagawa, Masataka Shimonosono, Prasanna M. Chandramouleeswaran, Takeo Hara, Varun Sahu, Yuta Kasagi, Osamu Kikuchi, Koji Tanaka, Veronique Giroux, Amanda B. Muir, Kelly A. Whelan, Shinya Ohashi, Seiji Naganuma, Andres J. Klein-Szanto, Yoshiaki Shinden, Ken Sasaki, Itaru Omoto, Yoshiaki Kita, Manabu Muto, Adam J. Bass, J. Alan Diehl, Gregory G. Ginsberg, Yuichiro Doki, Masaki Mori, Yasuto Uchikado, Takaaki Arigami, Narayan G. Avadhani, Devraj Basu, Anil K. Rustgi, Shoji Natsugoe
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY
(2019)